<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1458" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1458/" /><meta name="ncbi_pagename" content="Citrullinemia Type I - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Citrullinemia Type I - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Citrullinemia Type I" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/09/01" /><meta name="citation_author" content="Shane C Quinonez" /><meta name="citation_author" content="Jess G Thoene" /><meta name="citation_pmid" content="20301631" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1458/" /><meta name="citation_keywords" content="Argininosuccinate Synthetase Deficiency" /><meta name="citation_keywords" content="Argininosuccinic Acid Synthetase Deficiency" /><meta name="citation_keywords" content="ASS Deficiency" /><meta name="citation_keywords" content="Classic Citrullinemia" /><meta name="citation_keywords" content="CTLN1" /><meta name="citation_keywords" content="Argininosuccinate Synthetase Deficiency" /><meta name="citation_keywords" content="Argininosuccinic Acid Synthetase Deficiency" /><meta name="citation_keywords" content="ASS Deficiency" /><meta name="citation_keywords" content="Classic Citrullinemia" /><meta name="citation_keywords" content="CTLN1" /><meta name="citation_keywords" content="Argininosuccinate synthase" /><meta name="citation_keywords" content="ASS1" /><meta name="citation_keywords" content="Citrullinemia Type I" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Citrullinemia Type I" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Shane C Quinonez" /><meta name="DC.Contributor" content="Jess G Thoene" /><meta name="DC.Date" content="2016/09/01" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1458/" /><meta name="description" content="Citrullinemia type I (CTLN1) presents as a clinical spectrum that includes an acute neonatal form (the &quot;classic&quot; form), a milder late-onset form (the &quot;non-classic&quot; form), a form without symptoms or hyperammonemia, and a form in which women have onset of severe symptoms during pregnancy or post partum. Distinction between the clinical forms is based on clinical findings and is not clear-cut." /><meta name="og:title" content="Citrullinemia Type I" /><meta name="og:type" content="book" /><meta name="og:description" content="Citrullinemia type I (CTLN1) presents as a clinical spectrum that includes an acute neonatal form (the &quot;classic&quot; form), a milder late-onset form (the &quot;non-classic&quot; form), a form without symptoms or hyperammonemia, and a form in which women have onset of severe symptoms during pregnancy or post partum. Distinction between the clinical forms is based on clinical findings and is not clear-cut." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1458/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/ctlm/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1458/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE89C0A0E0415671000000000A8304D0.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1458_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1458_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/citrin/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/eds/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1458_"><span class="title" itemprop="name">Citrullinemia Type I</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Argininosuccinate Synthetase Deficiency, Argininosuccinic Acid Synthetase Deficiency, ASS Deficiency, Classic Citrullinemia, CTLN1</div><p class="contrib-group"><span itemprop="author">Shane C Quinonez</span>, MD and <span itemprop="author">Jess G Thoene</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1458_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1458_ai__"><div class="contrib half_rhythm"><span itemprop="author">Shane C Quinonez</span>, MD<div class="affiliation small">Clinical Assistant Professor<br />University of Michigan<br />Ann Arbor, Michigan<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.hcimu@noniuqs" class="oemail">ude.hcimu@noniuqs</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Jess G Thoene</span>, MD<div class="affiliation small">Active Emeritus Professor of Pediatrics<br />University of Michigan<br />Ann Arbor, Michigan<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.hcimu@eneohtj" class="oemail">ude.hcimu@eneohtj</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">July 7, 2004</span>; Last Update: <span itemprop="dateModified">September 1, 2016</span>.</p><p><em>Estimated reading time: 22 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="ctlm.Summary" itemprop="description"><h2 id="_ctlm_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Citrullinemia type I (CTLN1) presents as a clinical spectrum that includes an acute neonatal form (the "classic" form), a milder late-onset form (the "non-classic" form), a form without symptoms or hyperammonemia, and a form in which women have onset of severe symptoms during pregnancy or post partum. Distinction between the clinical forms is based on clinical findings and is not clear-cut.</p><p>Infants with the acute neonatal form appear normal at birth. Shortly thereafter, they develop hyperammonemia and become progressively lethargic, feed poorly, often vomit, and may develop signs of increased intracranial pressure (ICP). Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death. Children with the severe form who are treated promptly may survive for an indeterminate period of time, but usually with significant neurologic deficits.</p><p>The late-onset form may be milder than that seen in the acute neonatal form, for unknown reasons. The episodes of hyperammonemia are similar to those seen in the acute neonatal form, but the initial neurologic findings may be more subtle because of the older age of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of CTLN1 is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with elevated plasma ammonia concentration (&#x0003e;150 &#x000b5;mol/L; may range to &#x02265;2000-3000 &#x000b5;mol/L) and plasma citrulline concentration (usually &#x0003e;1000 &#x000b5;mol/L) and/or by the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>ASS1</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Acute management of hyperammonemia involves rapidly lowering plasma ammonia concentration using pharmacologic nitrogen scavenger therapy (sodium benzoate, sodium phenylacetate, and arginine) or hemodialysis, if scavenger therapy fails; reversal of catabolism via intravenous glucose infusion and intralipids or protein-free enteral nutrition, if tolerated; and control of intracranial pressure.</p><p>Chronic management involves lifelong dietary management to maintain plasma ammonia concentration lower than100 &#x000b5;mol/L and near-normal plasma glutamine concentration; oral administration of sodium phenylbutyrate or glycerol phenylbutyrate; L-carnitine to prevent systemic hypocarnitinemia. Liver transplantation, the only known cure for CTLN1, is best performed between age three months (and/or attainment of 5 kg body weight) and one year to decrease complications and improve survival; liver transplantation does not reverse any neurologic sequelae present at the time of transplant.</p><p><i>Prevention of secondary complications:</i> Medical attention during intercurrent infections to prevent hyperammonemia; routine vaccinations including annual influenza vaccine.</p><p><i>Surveillance:</i> Routine follow up in a metabolic clinic; monitoring for hyperammonemia and secondary deficiency of essential amino acids; monitoring older individuals for signs of impending hyperammonia (i.e., mood changes, headache, lethargy, nausea, vomiting, refusal to feed, ankle clonus) and elevated plasma glutamine concentration. Monitoring should be frequent in neonates and infants, based on disease severity, but may be extended to every six months to annually in older individuals, depending on clinical stability.</p><p><i>Agents/</i>c<i>ircumstances to avoid:</i> Excess protein intake; exposure to communicable diseases.</p><p><i>Evaluation of relatives at risk:</i> In utero diagnosis if the pathogenic variants in the family are known permits appropriate oral therapy beginning with the first feeds. Alternatively, sibs should be evaluated on day one of life by measurement of plasma concentrations of ammonia and citrulline; elevation of either above acceptable levels (ammonia &#x0003e;100 &#x000b5;mol/L or plasma citrulline &#x0003e;~100 &#x000b5;mol/L) is sufficient evidence to initiate treatment.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Citrullinemia type I is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for pregnancies at increased risk are possible if the pathogenic variants in the family are known.</p></div></div><div id="ctlm.Diagnosis"><h2 id="_ctlm_Diagnosis_">Diagnosis</h2><p>Citrullinemia type I (CTLN1) results from deficiency of the enzyme argininosuccinate synthase, the third step in the urea cycle, in which citrulline is condensed with aspartate to form arginosuccinic acid (see Urea Cycle Disorders Overview <a href="/books/n/gene/ucd-overview/figure/ucd-overview.F1/?report=objectonly" target="object" class="figpopup" rid-figpopup="figucdoverviewF1" rid-ob="figobucdoverviewF1">Figure 1</a>).</p><div id="ctlm.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Citrullinemia type I (CTLN1) <b>should be suspected</b> in individuals with the following <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> results, clinical features (by age), and supportive laboratory findings.</p><div id="ctlm.Newborn_Screening_Results"><h4>Newborn Screening Results</h4><p><b>Elevated citrulline</b> is detected in dried blood spots on newborn screen by tandem mass spectroscopy (MS/MS). Note: As of this writing, all states include CTLN1 in their <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> programs.</p></div><div id="ctlm.Clinical_Features"><h4>Clinical Features</h4><p><b>Neonatal presentation.</b> Sign and symptoms classically occur within the first week of life while on a full protein diet:</p><ul><li class="half_rhythm"><div>Increasing lethargy</div></li><li class="half_rhythm"><div>Somnolence</div></li><li class="half_rhythm"><div>Refusal to feed</div></li><li class="half_rhythm"><div>Vomiting</div></li><li class="half_rhythm"><div>Tachypnea</div></li><li class="half_rhythm"><div>Stroke</div></li><li class="half_rhythm"><div>Increased intracranial pressure (secondary to hyperammonemia) resulting in increased neuromuscular tone, spasticity, and ankle clonus</div></li></ul><p><b>Non-classic presentation.</b> Signs and symptoms may occur at any age and may not present as acutely as in the neonate:</p><ul><li class="half_rhythm"><div>Recurrent lethargy and somnolence</div></li><li class="half_rhythm"><div>Intense headache</div></li><li class="half_rhythm"><div>Scotomas</div></li><li class="half_rhythm"><div>Migraine-like episodes</div></li><li class="half_rhythm"><div>Ataxia and slurred speech</div></li><li class="half_rhythm"><div>Intellectual disability</div></li></ul></div><div id="ctlm.Supportive_Laboratory_Findings"><h4>Supportive Laboratory Findings</h4><p><b>Plasma ammonia concentration</b></p><ul><li class="half_rhythm"><div><b>Neonate.</b> Initial plasma ammonia concentration in the severe form may be 1000-3000 &#x000b5;mol/L (normal: 40-100 &#x000b5;mol/L).</div></li><li class="half_rhythm"><div><b>Late-onset.</b> Chronic or recurrent hyperammonemia, often with a lower plasma concentration than in the classic form (adult upper limit of normal: &#x0003c;60 &#x000b5;mol/L).</div></li></ul><p><b>Plasma quantitative amino acid analysis</b></p><ul><li class="half_rhythm"><div><b>Citrulline.</b> Usually &#x0003e;1000 &#x000b5;mol/L (normal: &#x0003c;50 &#x000b5;mol/L)</div></li><li class="half_rhythm"><div>Argininosuccinic acid. Absent</div></li><li class="half_rhythm"><div><b>Arginine and ornithine.</b> Low to normal range; see Urea Cycle Disorders Overview <a href="/books/n/gene/ucd-overview/figure/ucd-overview.F3/?report=objectonly" target="object" class="figpopup" rid-figpopup="figucdoverviewF3" rid-ob="figobucdoverviewF3">Figure 3</a>.</div></li><li class="half_rhythm"><div><b>Lysine, glutamine, and alanine</b>. Increased; these are surrogate markers of hyperammonemia.</div></li></ul><p><b>Urinary organic acids analysis.</b> Normal, although orotic acid may be detected as part of urinary organic acid analysis by gas chromatography/mass spectrometry. However, the <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> depends on the extraction method.</p></div></div><div id="ctlm.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of CTLN1 <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with elevated plasma ammonia concentration (&#x0003e;150 &#x000b5;mol/L; may range to &#x02265;2000-3000 &#x000b5;mol/L) and plasma citrulline concentration (usually &#x0003e;1000 &#x000b5;mol/L) and/or by the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>ASS1</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1458/table/ctlm.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figctlmTmoleculargenetictestingusedin" rid-ob="figobctlmTmoleculargenetictestingusedin">Table 1</a>).</p><p>Note: Determining the prognosis prospectively can be difficult in some individuals who fit the biochemical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> but may or may not have serious clinical illness.</p><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>ASS1</i> is performed first and followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>ASS1</i> and other genes of interest (see <a href="#ctlm.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div id="ctlm.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Citrullinemia Type I</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1458/table/ctlm.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ctlm.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ctlm.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_ctlm.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_ctlm.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_ctlm.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>ASS1</i></td><td headers="hd_h_ctlm.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_ctlm.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">96%&#x000a0;<sup>4,&#x000a0;5</sup></td></tr><tr><td headers="hd_h_ctlm.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></td><td headers="hd_h_ctlm.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 7</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="ctlm.TF.1.1"><p class="no_margin">See <a href="/books/NBK1458/#ctlm.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="ctlm.TF.1.2"><p class="no_margin">See <a href="#ctlm.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="ctlm.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="ctlm.TF.1.4"><p class="no_margin">In 80 individuals evaluated, both abnormal alleles were identified in 75 (94%), one abnormal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in four (5%), and no abnormal alleles in one (1%).</p></div></dd><dt>5. </dt><dd><div id="ctlm.TF.1.5"><p class="no_margin">Sequencing of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA from a variety of cells or <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> from cultured fibroblasts detected 154 of 160 (96%) abnormal alleles [H&#x000e4;berle, personal communication].</p></div></dd><dt>6. </dt><dd><div id="ctlm.TF.1.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods that may be used include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>7. </dt><dd><div id="ctlm.TF.1.7"><p class="no_margin">Exon and multiexon deletions were reported by <a class="bk_pop" href="#ctlm.REF.engel.2009.300">Engel et al [2009]</a>.</p></div></dd></dl></div></div></div><p><b>Argininosuccinate synthase (ASS) enzyme activity</b>. Incorporation of radiolabeled citrulline into argininosuccinic acid is measured in cultured fibroblasts (see also <a href="#ctlm.Prenatal_Testing_and_Preimplantatio">Prenatal Testing and Preimplantation Genetic Diagnosis</a>). ASS activity is also determined by a method based on the conversion of radiolabeled (<sup>14</sup>C)-aspartate to (<sup>14</sup>C)-argininosuccinate [<a class="bk_pop" href="#ctlm.REF.gao.2003.24">Gao et al 2003</a>]:</p><ul><li class="half_rhythm"><div>The normal enzyme activity in fibroblasts is 0.8-3.8 nmol/min/mg protein, but this is specific to tissue, method, and laboratory.</div></li><li class="half_rhythm"><div>Enzyme assay is not widely used because the clinical presentation and relatively specific pattern of metabolites found in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are sufficient to establish the diagnosis.</div></li></ul></div></div><div id="ctlm.Clinical_Characteristics"><h2 id="_ctlm_Clinical_Characteristics_">Clinical Characteristics</h2><div id="ctlm.Clinical_Description"><h3>Clinical Description</h3><p>Citrullinemia type I (CTLN1) presents as a spectrum that includes a neonatal acute form (the "classic" form), a milder late-onset form (the "non-classic" form), a form in which women have onset of symptoms at pregnancy or post partum, and a form without symptoms or hyperammonemia.</p><p><b>Neonatal ("classic") form.</b> The infant appears normal at birth. After an interval of one to a few days, the infant becomes progressively more lethargic, feeds poorly, may vomit, and may develop signs of increased intracranial pressure [<a class="bk_pop" href="#ctlm.REF.brusilow.2001">Brusilow &#x00026; Horwich 2001</a>]. Fifty-six percent of infants with classic citrullinemia type I are symptomatic by age four days and 67% by age one week [<a class="bk_pop" href="#ctlm.REF.bachmann.2003a.410">Bachmann 2003a</a>].</p><p>Children diagnosed and referred for appropriate treatment (see <a href="#ctlm.Management">Management</a>) survive for an indeterminate period of time, usually with significant neurologic deficits. All children with a peak plasma ammonia concentration greater than 480 &#x000b5;mol/L or an initial plasma ammonia concentration greater than 300 &#x000b5;mol/L have cognitive impairment [<a class="bk_pop" href="#ctlm.REF.bachmann.2003b.s29">Bachmann 2003b</a>]. The longest survival of an untreated infant with classic citrullinemia type I is 17 days.</p><p><b>Non-classic form.</b> The clinical course may be similar to or milder than that seen in the acute neonatal form, but commences later in life for reasons that are not completely understood. However, specific <i>ASS1</i> pathogenic variants may be associated with the non-classic form (see <a href="#ctlm.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a> and <a href="#ctlm.Molecular_Genetics">Molecular Genetics</a>). When episodes of hyperammonemia occur, they are similar to those seen in the acute neonatal form, but the neurologic findings may be more subtle because of the older age of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. These can include intense headache, scotomas, migraine-like episodes, ataxia, slurred speech, lethargy, and somnolence. Individuals with hyperammonemia also display respiratory alkalosis and tachypnea [<a class="bk_pop" href="#ctlm.REF.brusilow.2001">Brusilow &#x00026; Horwich 2001</a>]. Without prompt intervention, increased intracranial pressure occurs, with increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death.</p><p>Liver failure is now recognized as a primary presentation of CTLN1, contradicting established dogma of CNS symptoms as the primary finding [<a class="bk_pop" href="#ctlm.REF.salek.2010.1049">Salek et al 2010</a>, <a class="bk_pop" href="#ctlm.REF.faghfoury.2011.413">Faghfoury et al 2011</a>, <a class="bk_pop" href="#ctlm.REF.lee.2013.18">Lee et al 2013</a>, <a class="bk_pop" href="#ctlm.REF.r_egger.2014.21">R&#x000fc;egger et al 2014</a>]. Hepatic dysfunction, when present, is frequently noted at the time of the initial hyperammonemic episode but has also developed in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual who was not experiencing significant hyperammonemia (&#x0003e;250 &#x000b5;mol/L) at the time [<a class="bk_pop" href="#ctlm.REF.lee.2013.18">Lee et al 2013</a>].</p><p><b>Possible long-term complications.</b> An individual with classic citrullinemia treated with chronic protein restriction and scavenger therapy (see <a href="#ctlm.Treatment_of_Manifestations">Treatment of Manifestations</a>) developed progressive hypertrophic cardiomyopathy (diagnosed at age 23 years) and bilateral cataracts (diagnosed at age 27 years) [<a class="bk_pop" href="#ctlm.REF.brunettipierri.2012.248">Brunetti-Pierri et al 2012</a>]. No additional individuals with classic CTLN1 have been identified with similar findings. As such, the necessity for cardiac and ophthalmologic surveillance remains controversial until more <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have been studied.</p><p><b>Pregnancy.</b> A healthy woman with untreated CTLN1 underwent two successful pregnancies [<a class="bk_pop" href="#ctlm.REF.potter.2004.77">Potter et al 2004</a>]; however, women with onset of severe symptoms during pregnancy or in the postpartum period have been reported [<a class="bk_pop" href="#ctlm.REF.gao.2003.24">Gao et al 2003</a>, <a class="bk_pop" href="#ctlm.REF.ruitenbeek.2003.102">Ruitenbeek et al 2003</a>].</p><ul><li class="half_rhythm"><div>Three women not known to have citrullinemia presented in hyperammonemic coma shortly after delivery; one died and two survived without neurologic sequelae [<a class="bk_pop" href="#ctlm.REF.h_berle.2009.1">H&#x000e4;berle et al 2009</a>].</div></li><li class="half_rhythm"><div>CTLN1 has been implicated in postpartum psychosis [<a class="bk_pop" href="#ctlm.REF.h_berle.2010.228">H&#x000e4;berle et al 2010</a>].</div></li></ul><p>Individuals remaining asymptomatic up to at least age ten years have been reported; it appears that they could remain asymptomatic lifelong [<a class="bk_pop" href="#ctlm.REF.h_berle.2002.327">H&#x000e4;berle et al 2002</a>, <a class="bk_pop" href="#ctlm.REF.h_berle.2003.302">H&#x000e4;berle et al 2003</a>].</p><p><b>Neuroimaging.</b> CT scan of infants with citrullinemia type I demonstrates cerebral atrophy, particularly in the cingulate gyrus, the insula, and the temporal lobes, as well as general cortical hypo-attenuation (i.e., the cortex appears darker than in unaffected individuals) [<a class="bk_pop" href="#ctlm.REF.albayram.2002.334">Albayram et al 2002</a>].</p><p>Brain MRI findings in classic citrullinemia include restricted diffusion and T<sub>2</sub> signal hyperintensities in the basal ganglia, thalami, and subcortical white matter of the bilateral temporal, parietal, and occipital cortex [<a class="bk_pop" href="#ctlm.REF.majoie.2004.32">Majoie et al 2004</a>, <a class="bk_pop" href="#ctlm.REF.bireley.2012.455">Bireley et al 2012</a>]. Multicystic encephalomalacia and cerebral atrophy have been seen as early as age three to four months in an individual with classic CTLN1 [<a class="bk_pop" href="#ctlm.REF.lee.2013.18">Lee et al 2013</a>].</p></div><div id="ctlm.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Although certain pathogenic variants are identified with some phenotypes, the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> cannot be predicted in all instances [<a class="bk_pop" href="#ctlm.REF.engel.2009.300">Engel et al 2009</a>].</p><ul><li class="half_rhythm"><div>Severe, classic citrullinemia type I typically results from 22 defined pathogenic variants [<a class="bk_pop" href="#ctlm.REF.engel.2009.300">Engel et al 2009</a>]. The <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 15, <a class="figpopup" href="/books/NBK1458/table/ctlm.T.ass1_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figctlmTass1pathogenicvariantsdiscusse" rid-ob="figobctlmTass1pathogenicvariantsdiscusse">p.Gly390Arg</a>, remains the most prevalent associated with the classic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#ctlm.REF.engel.2009.300">Engel et al 2009</a>, <a class="bk_pop" href="#ctlm.REF.lar_vere.2009.1166">Lar&#x000f3;vere et al 2009</a>].</div></li><li class="half_rhythm"><div>Mild (i.e., late-onset) citrullinemia type I is associated with 12 pathogenic variants [<a class="bk_pop" href="#ctlm.REF.engel.2009.300">Engel et al 2009</a>].</div></li></ul></div><div id="ctlm.Nomenclature"><h3>Nomenclature</h3><p>The preferred terms for argininosuccinic acid synthetase deficiency are "citrullinemia type I" and "classic citrullinemia," which are used to avoid confusion with the genetically distinct disease, citrullinemia type II, also known as <a href="/books/n/gene/citrin/">citrin deficiency</a>.</p></div><div id="ctlm.Prevalence"><h3>Prevalence</h3><p>Citrullinemia type I has been estimated to occur in 1:57,000 births [<a class="bk_pop" href="#ctlm.REF.brusilow.2001">Brusilow &#x00026; Horwich 2001</a>].</p><p>Newborn screening programs found CTLN1 in the following:</p><ul><li class="half_rhythm"><div>In Korea: two in 44,300 newborns [<a class="bk_pop" href="#ctlm.REF.yoon.2003.115">Yoon et al 2003</a>]</div></li><li class="half_rhythm"><div>In New England: one in 200,000 newborns [<a class="bk_pop" href="#ctlm.REF.marsden.2003.111">Marsden 2003</a>]</div></li><li class="half_rhythm"><div>In Taiwan: five (2 severe and 3 mild) in a pilot program of 592,717 newborns; overall incidence 1:118,543 [<a class="bk_pop" href="#ctlm.REF.niu.2010.s295">Niu et al 2010</a>]</div></li><li class="half_rhythm"><div>In Austria: 1:77,811 among 622,489 newborns [<a class="bk_pop" href="#ctlm.REF.kasper.2010.607">Kasper et al 2010</a>]</div></li><li class="half_rhythm"><div>In Texas, New York, Michigan, California, Massachusetts, North Carolina and Wisconsin, estimated combined prevalence of CTLN1 and ASLD: one in 117,000 [<a class="bk_pop" href="#ctlm.REF.summar.2013.179">Summar et al 2013</a>]</div></li></ul></div></div><div id="ctlm.Genetically_Related_Allelic_Disorde"><h2 id="_ctlm_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>ASS1</i>.</p></div><div id="ctlm.Differential_Diagnosis"><h2 id="_ctlm_Differential_Diagnosis_">Differential Diagnosis</h2><p>Conditions that may result in elevated citrulline on <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> are citrullinemia II (citrin deficiency), argininosuccinic aciduria, and pyruvate carboxylase deficiency.</p><p><a href="/books/n/gene/citrin/">Citrullinemia type II</a> (CTLN2) is caused by citrin deficiency resulting from <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>SLC25A13</i>, which encodes the mitochondrial solute <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> protein, citrin. In citrin deficiency aspartate and glutamate fail to shuttle to and from the mitochondrion, leading to mild hyperammonemia and citrullinemia. Biallelic pathogenic variants in <i>SLC25A13</i> also lead to intrahepatic cholestasis in the neonate [<a class="bk_pop" href="#ctlm.REF.saheki.2002.333">Saheki &#x00026; Kobayashi 2002</a>]. The clinical course in adults with citrullinemia type II is milder than that of CTLN1, possibly distinguishing it from milder late-onset citrullinemia type I. It is not known why CTLN2 is milder and later in onset than CTLN1; distinguishing between the two disorders is difficult. The prevalence of citrullinemia type II has not been reported.</p><p>It is critical to distinguish hyperammonemia caused by a defect in the urea cycle from the secondary hyperammonemia caused by an organic acidemia, which may cause inhibition of N-acetylglutamate synthase (see Urea Cycle Disorders Overview <a href="/books/n/gene/ucd-overview/figure/ucd-overview.F2/?report=objectonly" target="object" class="figpopup" rid-figpopup="figucdoverviewF2" rid-ob="figobucdoverviewF2">Figure 2</a>).</p><p><a href="/books/n/gene/dld-def/">Dihydrolipoamide dehydrogenase (DLD) deficiency</a> has also been reported to display increased citrulline, ammonia and glutamine [<a class="bk_pop" href="#ctlm.REF.haviv.2014.243">Haviv et al 2014</a>]. DLD deficiency is caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>DLD</i>.</p><p>Classic citrullinemia type I shares the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of the typical acute neonatal hyperammonemia displayed by other defects in the first four steps in the urea cycle pathway. The mild phenotype shares a later onset with other disorders such as late-onset <a href="/books/n/gene/otc-def/">ornithine transcarbamylase (OTC) deficiency</a>. Urea Cycle Disorders Overview <a href="/books/n/gene/ucd-overview/figure/ucd-overview.F3/?report=objectonly" target="object" class="figpopup" rid-figpopup="figucdoverviewF3" rid-ob="figobucdoverviewF3">Figure 3</a> shows a diagnostic strategy to identify which steps in the urea cycle are defective in an individual with hyperammonemia.</p></div><div id="ctlm.Management"><h2 id="_ctlm_Management_">Management</h2><div id="ctlm.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with citrullinemia type I (CTLN1), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Measurement of: concentration of plasma ammonia, amino acids, and electrolytes; blood gases; urinary organic acids; and urinary orotic acid</div></li><li class="half_rhythm"><div>Assessment of intracranial pressure and overall neurologic status</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist</div></li></ul></div><div id="ctlm.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>As soon as a diagnosis of CTLN1 is made, acute (if needed) and chronic management should be initiated per established treatment guidelines [<a class="bk_pop" href="#ctlm.REF.batshaw.2001.s46">Batshaw et al 2001</a>, <a class="bk_pop" href="#ctlm.REF.summar.2001.s30">Summar 2001</a>, UCD Conference Group 2001]. See <a href="http://www.acmg.net/PDFLibrary/Citrullinemia.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ACMG-ACT Sheet</a>, <a href="http://www.acmg.net/PDFLibrary/Citrulline-Algorithm.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ACMG Algorithm</a>.</p><div id="ctlm.Acute_Management_of_Hyperammonemia"><h4>Acute Management of Hyperammonemia</h4><p>Hallmarks of therapy include rapid lowering of the plasma ammonia concentration, reversal of catabolism, and avoidance and/or treatment of increased intracranial pressure [<a class="bk_pop" href="#ctlm.REF.h_berle.2012.32">H&#x000e4;berle et al 2012</a>].</p><p><b>Rapidly decreasing plasma ammonia concentration.</b> When hyperammonemia is diagnosed or suspected, all protein intake should be withheld for a maximum of 24-48 hours. This time frame allows for the plasma ammonia concentration to be lowered via <b>nitrogen scavenger therapy</b> and/or <b>dialysis</b> and avoids an essential amino acid deficiency that would promote a catabolic state:</p><ul><li class="half_rhythm"><div><b>Pharmacologic nitrogen scavenger therapy</b> (sodium benzoate, sodium phenylacetate and arginine) should be given intravenously as soon as hyperammonemia is diagnosed in an individual known to have CTLN1. (For information pertaining to the mechanism of action of this treatment, see <a href="/books/NBK1458/bin/ctlm-scavenger_therapy.pdf">Scavenger Therapy</a>.)</div><ul><li class="half_rhythm"><div>Priming infusion (to be given continuously over 90 minutes):</div><ul><li class="half_rhythm"><div>Sodium benzoate: 250 mg/kg or 5.5 g/m<sup>2</sup></div></li><li class="half_rhythm"><div>Sodium phenylacetate: 250 mg/kg or 5.5 g/m<sup>2</sup></div></li><li class="half_rhythm"><div>10% arginine HCl: 600 mg/kg or 12.0 g/m<sup>2</sup></div></li></ul></li><li class="half_rhythm"><div>Sustaining infusion (to be given continuously over 24 hours):</div><ul><li class="half_rhythm"><div>Sodium benzoate: 250 mg/kg or 5.5 g/m<sup>2</sup></div></li><li class="half_rhythm"><div>Sodium phenylacetate: 250 mg/kg or 5.5 g/m<sup>2</sup></div></li><li class="half_rhythm"><div>10% arginine HCl: 600 mg/kg or 12.0 g/m<sup>2</sup></div></li></ul></li><li class="half_rhythm"><div>Note: Repeat boluses are not recommended unless the individual is receiving dialysis (see following).</div></li></ul></li><li class="half_rhythm"><div><b>Dialysis</b> is the most effective means of reducing plasma ammonia rapidly. Failure to control ammonia with scavenger therapy requires the emergency use of dialysis.</div><ul><li class="half_rhythm"><div>Hemodialysis is the preferred method of dialysis and exceeds both peritoneal dialysis and hemofiltration in the rate of ammonia clearance.</div></li><li class="half_rhythm"><div>Scavenger therapy should be continued while dialysis is being performed.</div></li><li class="half_rhythm"><div>Note: Exchange transfusions have no place in hyperammonemic treatment.</div></li></ul></li></ul><p><b>Reversal of catabolism.</b> An anabolic state should be promoted through the provision of IV glucose (and insulin in the event of hyperglycemia) and intralipids.</p><ul><li class="half_rhythm"><div>Complete protein restriction should be limited to 24-48 hours to avoid a catabolic state.</div></li><li class="half_rhythm"><div>In small infants, 40 kcal/100 mL given as D10W can be significant in averting catabolism. As soon as possible, osmolar load permitting, the individual should receive total parenteral nutrition (TPN) providing 0.25 g/kg/day of protein and 50 kcal/kg/day, advancing (as plasma ammonia concentration allows) to 1.0-1.5 g/kg/day of protein and 100-120 kcal/kg/day. Standard TPN solutions of dextrose, aminosol, and intralipid are used.</div></li></ul><p><b>Control of intracranial pressure.</b> It is critical to monitor fluid balance, intake and output, and body weight.</p><ul><li class="half_rhythm"><div>The <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual should be maintained on the dry side of fluid balance: approximately 85 mL/kg of body weight per day in infants and appropriate corresponding fluid restriction in children and adults.</div></li><li class="half_rhythm"><div>Increased intracranial pressure is manifested by tension in the fontanelle, acute enlargement of the liver, edema, and worsening neurologic signs including fisting, scissoring, ankle clonus, and coma. Cerebral edema and ischemia may be documented by MRI.</div></li></ul></div><div id="ctlm.Chronic_Management"><h4>Chronic Management</h4><p>Chronic therapy for those with CTLN1 consists of lifelong protein restriction, medications (nitrogen scavenger therapy and carnitine), and possible liver transplantation based on the degree of metabolic control achieved with dietary modification and medication therapy.</p><p><b>Protein restriction.</b> Lifelong dietary management is necessary and requires the services of a metabolic nutritionist.</p><p><b>Nitrogen scavenger therapy</b></p><ul><li class="half_rhythm"><div>When the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual is able to tolerate solid food, the oral medication sodium phenylbutyrate (Buphenyl<sup>&#x000ae;</sup>, Ammonaps<sup>&#x000ae;</sup>), at a dose of 450-600 mg/kg/day divided into three doses, and arginine-free base of 400 and 700 mg/kg/day are begun. As children grow, doses change to 9.9-13 g/m<sup>2</sup>/day of sodium phenylbutyrate and 8.8-15.4 g/m<sup>2</sup>/day of arginine. For details of management, the reader is referred to <a class="bk_pop" href="#ctlm.REF.brusilow.2001">Brusilow &#x00026; Horwich [2001]</a> and <a class="bk_pop" href="#ctlm.REF.h_berle.2012.32">H&#x000e4;berle et al [2012]</a>.</div></li><li class="half_rhythm"><div>Glycerol phenylbutyrate (Ravicti<sup>&#x000ae;</sup>) is a more palatable option. The initial dosage for phenylbutyrate-na&#x000ef;ve patients is 4.5-11.2 mL/m<sup>2</sup>/day (5-12.4 g/m<sup>2</sup>/day). If the individual is transitioning from sodium phenylbutyrate to glycerol phenylbutyrate, the daily dose of glycerol phenylbutyrate (mL) = daily dose of sodium phenylbutyrate (g) x 0.86.</div></li><li class="half_rhythm"><div>Success of therapy is defined by a plasma ammonia concentration lower than100 &#x000b5;mol/L and near-normal plasma glutamine concentration. Plasma arginine concentration may be up to 250% above upper normal limit for age.</div></li><li class="half_rhythm"><div>Treatment with L-carnitine has been advocated as auxiliary treatment to prevent systemic hypocarnitinemia, which may result from therapy with acylating agents.</div></li></ul><p><b>Liver transplantation</b> for urea cycle disorders is the only known curative therapy [<a class="bk_pop" href="#ctlm.REF.morioka.2005.1332">Morioka et al 2005</a>]. Transplantation eliminates the need for dietary protein restriction but does not reverse any neurologic sequelae that <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals may have at the time of transplant.</p><p>Liver transplantation should ideally be performed in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals who are younger than age one year (prior to the development of any neurocognitive impairment) but older than age three months and/or above 5 kg body weight, to decrease complications and improve survival rates [<a class="bk_pop" href="#ctlm.REF.h_berle.2012.32">H&#x000e4;berle et al 2012</a>].</p><ul><li class="half_rhythm"><div class="half_rhythm">Liver transplantation of four individuals with CTLN1 between the ages of six and 64 months showed better developmental outcomes when the transplant was performed at earlier ages [<a class="bk_pop" href="#ctlm.REF.kim.2013.158">Kim et al 2013</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Survival rates in those who underwent liver transplantation prior to age two years was between 90% and 95% five years post transplant [<a class="bk_pop" href="#ctlm.REF.bourdeaux.2007.440">Bourdeaux et al 2007</a>, <a class="bk_pop" href="#ctlm.REF.perito.2014.89">Perito et al 2014</a>].</div><div class="half_rhythm">Note: Although liver transplantation cures the ASS enzyme deficiency, arginine is extrahepatically synthesized and remains low post-transplantation, requiring ongoing supplementation.</div></li><li class="half_rhythm"><div class="half_rhythm">Living related-donor liver transplantation</div><ul><li class="half_rhythm"><div>A successful living related-donor liver transplantation (240 g) from mother to six-year-old daughter has been reported. The allopurinol challenge test was normalized in this child, who previously had very brittle control with four to six hyperammonemic episodes per year [<a class="bk_pop" href="#ctlm.REF.ito.2003.87">Ito et al 2003</a>].</div></li><li class="half_rhythm"><div>A living related-donor liver transplantation from mother to son resulted in continued elevation in plasma concentration of citrulline (200-400 &#x000b5;mol/L). The mother, a <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a>, had 28% residual ASS1 enzyme activity [<a class="bk_pop" href="#ctlm.REF.ando.2003.143">Ando et al 2003</a>].</div></li></ul></li></ul></div></div><div id="ctlm.Prevention_of_Primary_Manifestation"><h3>Prevention of Primary Manifestations</h3><p>Prevention of hyperammonemia is achieved through lifelong protein restriction, nitrogen scavenger therapy, and possible liver transplantation based on metabolic control (see <a href="#ctlm.Treatment_of_Manifestations">Treatment of Manifestations</a>).</p></div><div id="ctlm.Prevention_of_Secondary_Complicatio"><h3>Prevention of Secondary Complications</h3><p>Intercurrent infections (particularly some viral exanthems) may induce a catabolic state. Affected individuals must be observed carefully during such episodes and medical attention sought to prevent hyperammonemia.</p><p>Age-appropriate immunizations including the influenza vaccine should be provided.</p></div><div id="ctlm.Surveillance"><h3>Surveillance</h3><p>Follow up in a metabolic clinic with a qualified metabolic nutritionist and clinical biochemical geneticist is required. Monitoring should include:</p><ul><li class="half_rhythm"><div>Evaluation of early warning signs of impending hyperammonemic episodes including mood changes, headache, lethargy, nausea, vomiting, refusal to feed, and ankle clonus;</div></li><li class="half_rhythm"><div>Plasma ammonia and amino acid analysis to identify hyperammonemia and deficiency of essential amino acids and impending hyperammonemia, respectively. Plasma glutamine concentration may rise 48 hours in advance of increases in plasma ammonia concentration [<a class="bk_pop" href="#ctlm.REF.brusilow.2001">Brusilow &#x00026; Horwich 2001</a>].</div></li></ul><p>Monitoring should occur frequently in neonates and infants, based on disease severity.</p><p>As <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals become older (teenage years and adulthood), clinical and biochemical monitoring can be extended to every six months to annually depending on clinical stability.</p></div><div id="ctlm.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Avoid the following:</p><ul><li class="half_rhythm"><div>Excess protein intake</div></li><li class="half_rhythm"><div>Obvious exposure to communicable diseases</div></li></ul></div><div id="ctlm.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>Because the long-term prognosis for individuals with citrullinemia type I depends on initial and peak plasma ammonia concentration, it is important that at-risk sibs be identified as soon as possible.</p><p>Evaluations can include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the pathogenic variants in the family are known; in utero diagnosis (which permits appropriate oral therapy beginning with first feeds), if possible, is preferred.</div></li><li class="half_rhythm"><div>Measurement of plasma concentrations of ammonia and citrulline on day one of life. Elevation of either above acceptable levels (ammonia &#x0003e;100 &#x000b5;mol/L or plasma citrulline &#x0003e;~100 &#x000b5;mol/L) is sufficient evidence to initiate treatment.</div></li></ul><p>See <a href="#ctlm.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="ctlm.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Because women with onset of severe symptoms during pregnancy or in the postpartum period have been reported, scrupulous attention needs to be paid to diet and medication during these periods.</p></div><div id="ctlm.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Gene therapy has been suggested; success has not been achieved to date.</p><p>Phase I and Phase II clinical trials to assess the safety and efficacy of human hepatocyte transplantation as either an alternative to liver transplantation or as a temporizing measure for individuals with CTLN1 awaiting transplantation has recently finished.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div><div id="ctlm.Other"><h3>Other</h3><p>Ketoacids of essential amino acids were an early form of auxiliary waste nitrogen disposal enhancement, now replaced by the agents described in <a href="#ctlm.Treatment_of_Manifestations">Treatment of Manifestations</a>.</p></div></div><div id="ctlm.Genetic_Counseling"><h2 id="_ctlm_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="ctlm.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Citrullinemia type I (CTNL1) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="ctlm.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>ASS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) have no symptoms of the urea cycle defect <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. One case of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> who developed cirrhosis has been reported [<a class="bk_pop" href="#ctlm.REF.g__er.2004.541">G&#x000fc;&#x000e7;er et al 2004</a>].</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) have no symptoms of the urea cycle defect <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. One case of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> who developed cirrhosis has been reported [<a class="bk_pop" href="#ctlm.REF.g__er.2004.541">G&#x000fc;&#x000e7;er et al 2004</a>].</div></li><li class="half_rhythm"><div>Sibs should be evaluated immediately after birth and placed on a protein-restricted diet until the diagnostic evaluation is complete (see <a href="#ctlm.Management">Management</a>).</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with CTNL1 are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ASS1</i>.</p><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each sib of the proband's parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an <i>ASS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="ctlm.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>ASS1</i> pathogenic variants in the family.</p></div><div id="ctlm.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#ctlm.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="ctlm.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Prenatal diagnosis for pregnancies at 25% risk is possible. Methods of <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> include:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Molecular genetic testing.</b> Once the <i>ASS1</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Argininosuccinate synthase enzyme activity</b> can be measured in uncultured fetal tissue obtained by chorionic villus sampling (CVS) or cultured amniocytes obtained by amniocentesis if the <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> pathogenic <i>ASS1</i> variants have not been identified.</div><div class="half_rhythm">Note: Improvement in diagnostic accuracy using the ratio of citrulline to ornithine and arginine concentrations in amniotic fluid has been reported [<a class="bk_pop" href="#ctlm.REF.chadefauxvekemans.2002.456">Chadefaux-Vekemans et al 2002</a>].</div></li></ul></div></div><div id="ctlm.Resources"><h2 id="_ctlm_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Citrullinemia%20type%201&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Citrullinemia type 1</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=citrullinemia" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Citrullinemia</a></div></li><li class="half_rhythm"><div><b>National Urea Cycle Disorders Foundation</b></div><div>75 South Grand Avenue</div><div>Pasadena CA 91105</div><div><b>Phone:</b> 800-386-8233 (toll-free); 626-578-0833</div><div><b>Fax:</b> 626-578-0823</div><div><b>Email:</b> info@nucdf.org</div><div><a href="http://www.nucdf.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nucdf.org</a></div></li><li class="half_rhythm"><div><b>Metabolic Support UK</b></div><div>5 Hilliards Court, Sandpiper Way</div><div>Chester Business Park</div><div>Chester CH4 9QP </div><div>United Kingdom</div><div><b>Phone:</b> 0845 241 2173</div><div><b>Email:</b> contact@metabolicsupportuk.org</div><div><a href="https://www.metabolicsupportuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.metabolicsupportuk.org</a></div></li><li class="half_rhythm"><div><b>Save Babies Through Screening Foundation, Inc.</b></div><div>P. O. Box 42197</div><div>Cincinnati OH 45242</div><div><b>Phone:</b> 888-454-3383</div><div><b>Email:</b> email@savebabies.org</div><div><a href="http://www.savebabies.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.savebabies.org</a></div></li><li class="half_rhythm"><div><b>European Registry and Network for Intoxication Type Metabolic Diseases (E-IMD)</b></div><div><a href="https://www.e-imd.org/event/european-registry-and-network-intoxication-type-metabolic-diseases" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.e-imd.org/en/index.phtml</a></div></li><li class="half_rhythm"><div><b>Urea Cycle Disorder International Patient Registry</b></div><div><b>Phone:</b> 626-578-0833</div><div><b>Fax:</b> 626-578-0823</div><div><b>Email:</b> coordinator@ucdparegistry.org</div><div><a href="https://ucdparegistry.patientcrossroads.org/index.php?option=com_content&#x00026;view=article&#x00026;id=412&#x00026;Itemid=484" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ucdregistry.org</a></div></li><li class="half_rhythm"><div><b>Urea Cycle Disorders Consortium Registry</b></div><div>Children's National Medical Center</div><div><b>Phone:</b> 202-306-6489</div><div><b>Email:</b> jseminar@childrensnational.org</div><div><a href="https://www.rarediseasesnetwork.org/cms/ucdc/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.rarediseasesnetwork.org/cms/ucdc/</a></div></li></ul></div><div id="ctlm.Molecular_Genetics"><h2 id="_ctlm_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="ctlm.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Citrullinemia Type I: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1458/table/ctlm.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ctlm.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_ctlm.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_ctlm.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_ctlm.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_ctlm.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_ctlm.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_ctlm.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_ctlm.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/445" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ASS1</i></a></td><td headers="hd_b_ctlm.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=445" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">9q34<wbr style="display:inline-block"></wbr>​.11</a></td><td headers="hd_b_ctlm.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P00966" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Argininosuccinate synthase</a></td><td headers="hd_b_ctlm.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/ASS1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ASS1 @ LOVD</a></td><td headers="hd_b_ctlm.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ASS1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ASS1</a></td><td headers="hd_b_ctlm.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ASS1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ASS1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="ctlm.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="ctlm.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Citrullinemia Type I (<a href="/omim/215700,603470" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1458/table/ctlm.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ctlm.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/215700" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">215700</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CITRULLINEMIA, CLASSIC</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/603470" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">603470</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ARGININOSUCCINATE SYNTHETASE 1; ASS1</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>ASS1</i> comprises 16 exons; the primary transcript is 1239 bp. Transcription starts near the 5' end of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 3. At least 14 <i>ASS1</i> pseudogenes are known. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1458/#ctlm.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign (or mild clinical disease) allelic variants.</b> In the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> state p.Gly362Val is associated with mild or no clinical symptoms, as is compound heterozygosity for c.[323G&#x0003e;T];[970+5G&#x0003e;A] [<a class="bk_pop" href="#ctlm.REF.h_berle.2002.327">H&#x000e4;berle et al 2002</a>]. Fifty percent of individuals with non-classic presentations were found to be homozygous for one of the the following three <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants: p.Trp179Arg, p.Val263Met, or p.Gly362Val [<a class="bk_pop" href="#ctlm.REF.r_egger.2014.21">R&#x000fc;egger et al 2014</a>].</p><div id="ctlm.T.ass1_variants_associated_with_mil" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p><i>ASS1</i> Variants Associated with Mild or No Clinical Symptoms</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1458/table/ctlm.T.ass1_variants_associated_with_mil/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ctlm.T.ass1_variants_associated_with_mil_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Genotype&#x000a0;<sup>1,&#x000a0;2</sup></th><th id="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Homozygous</td><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.257G&#x0003e;A</td><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg86His</td><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_4" rowspan="8" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?val=NM_000050.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000050<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/entrez/viewer.fcgi?val=NP_000041.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000041<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Homozygous</td><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.535T&#x0003e;C</td><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp179Arg</td></tr><tr><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Homozygous</td><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.787G&#x0003e;A</td><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val263Met</td></tr><tr><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Homozygous</td><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.794G&#x0003e;A</td><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg265His</td></tr><tr><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Homozygous</td><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.851C&#x0003e;T</td><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr284Ile</td></tr><tr><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Homozygous</td><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1085G&#x0003e;T</td><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly362Val</td></tr><tr><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Compound <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a></td><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.[323G&#x0003e;T];[970+5G&#x0003e;A]</td><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Homozygous</td><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.773+49C&#x0003e;T</td><td headers="hd_h_ctlm.T.ass1_variants_associated_with_mil_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="ctlm.TF.2.1"><p class="no_margin"><a class="bk_pop" href="#ctlm.REF.h_berle.2002.327">H&#x000e4;berle et al [2002]</a></p></div></dd><dt>2. </dt><dd><div id="ctlm.TF.2.2"><p class="no_margin"><a class="bk_pop" href="#ctlm.REF.engel.2009.300">Engel et al [2009]</a></p></div></dd></dl></div></div></div><p><b>Pathogenic variants.</b>
<a class="bk_pop" href="#ctlm.REF.engel.2009.300">Engel et al [2009]</a> defined 87 <i>ASS1</i> pathogenic variants from all available ethnicities; 27 were previously undescribed. They were found to occur in most exons and several intervening sequences leading to abnormal <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a>. Seven variants are associated with severe disease; three of them (p.Arg304Trp, c.421-2A&#x0003e;G, and p.Gly390Arg) account for the majority of citrullinemia type I [<a class="bk_pop" href="#ctlm.REF.gao.2003.24">Gao et al 2003</a>], See <a href="#ctlm.GenotypePhenotype_Correlations">Genotype- Phenotype Correlations</a> and <a class="figpopup" href="/books/NBK1458/table/ctlm.T.ass1_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figctlmTass1pathogenicvariantsdiscusse" rid-ob="figobctlmTass1pathogenicvariantsdiscusse">Table 3</a>.</p><div id="ctlm.T.ass1_pathogenic_variants_discusse" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p><i>ASS1</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1458/table/ctlm.T.ass1_pathogenic_variants_discusse/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ctlm.T.ass1_pathogenic_variants_discusse_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ctlm.T.ass1_pathogenic_variants_discusse_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_ctlm.T.ass1_pathogenic_variants_discusse_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_ctlm.T.ass1_pathogenic_variants_discusse_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_ctlm.T.ass1_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.257G&#x0003e;A</td><td headers="hd_h_ctlm.T.ass1_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg86His&#x000a0;<sup>2</sup></td><td headers="hd_h_ctlm.T.ass1_pathogenic_variants_discusse_1_1_1_3" rowspan="5" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?val=NM_000050.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000050<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/entrez/viewer.fcgi?val=NP_000041.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000041<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_ctlm.T.ass1_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.421-2A&#x0003e;G<br />(IVS6-2A&#x0003e;G)</td><td headers="hd_h_ctlm.T.ass1_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_ctlm.T.ass1_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.794G&#x0003e;A</td><td headers="hd_h_ctlm.T.ass1_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg265His&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_ctlm.T.ass1_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.910C&#x0003e;T</td><td headers="hd_h_ctlm.T.ass1_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg304Trp</td></tr><tr><td headers="hd_h_ctlm.T.ass1_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1168G&#x0003e;A</td><td headers="hd_h_ctlm.T.ass1_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly390Arg</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="ctlm.TF.3.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="ctlm.TF.3.2"><p class="no_margin">Associated with late-onset citrullinemia type I; see <a href="#ctlm.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The translational product, argininosuccinate synthase, is a homotetramer of 186 kd. It catalyzes an essential reaction in the biosynthesis of urea, causing the condensation of citrulline and aspartate to argininosuccinic acid in the cytosol, and requiring 1 mol of ATP.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The argininosuccinate synthase enzyme is inactive or absent. Mutated ASS with abnormal K<sub>M</sub> (Michaelis constant) or very low ASS protein detected by ELISA using anti-ASS antibody (low CRIM: cross-reacting immunologic materials) has been found.</p></div><div id="ctlm.References"><h2 id="_ctlm_References_">References</h2><div id="ctlm.Published_Guidelines__Consensus_Sta"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF1">The Urea Cycle Disorders Conference Group. Consensus statement from a conference for the management of patients with urea cycle disorders. Available <a href="http://www.sciencedirect.com/science/article/pii/S0022347601278950" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2001. Accessed 5-29-19. [<a href="/pubmed/11148543" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11148543</span></a>]</div></li></ul></div><div id="ctlm.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.albayram.2002.334">Albayram S, Murphy KJ, Gailloud P, Moghekar A, Brunberg JA. CT findings in the infantile form of citrullinemia. <span><span class="ref-journal">AJNR Am J Neuroradiol. </span>2002;<span class="ref-vol">23</span>:334–6.</span> [<a href="/pubmed/11847065" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11847065</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.ando.2003.143">Ando T, Fuchinoue S, Shiraga H, Ito K, Shimoe T, Wada N, Kobayashi K, Saeki T, Teraoka S. Living-related liver transplantation for citrullinemia: different features and clinical problems between classical types (CTLN1) and adult-onset type (CTLN2) citrullinemia. <span><span class="ref-journal">Japan J Transplant. </span>2003;<span class="ref-vol">38</span>:143–7.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.bachmann.2003a.410">Bachmann C. Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation. <span><span class="ref-journal">Eur J Pediatr. </span>2003a;<span class="ref-vol">162</span>:410–6.</span> [<a href="/pubmed/12684900" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12684900</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.bachmann.2003b.s29">Bachmann C. Long-term outcome of patients with urea cycle disorders and the question of neonatal screening. <span><span class="ref-journal">Eur J Pediatr. </span>2003b;<span class="ref-vol">162</span> Suppl 1:S29–33.</span> [<a href="/pubmed/14634803" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14634803</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.batshaw.2001.s46">Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: Twenty years later. <span><span class="ref-journal">J Pediatr. </span>2001;<span class="ref-vol">138</span>:S46–S54.</span> [<a href="/pubmed/11148549" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11148549</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.bireley.2012.455">Bireley WR, Van Hove JL, Gallagher RC, Fenton LZ. Urea cycle disorders: brain MRI and neurological outcome. <span><span class="ref-journal">Pediatr Radiol. </span>2012;<span class="ref-vol">42</span>:455–62.</span> [<a href="/pubmed/21989980" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21989980</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.bourdeaux.2007.440">Bourdeaux C, Darwish A, Jamart J, Tri TT, Janssen M, Lerut J, Otte JB, Sokal E, de Ville de Goyet J, Reding R. Living-related versus deceased donor pediatric liver transplantation: a multivariate analysis of technical and immunological complications in 235 recipients. <span><span class="ref-journal">Am J Transplant. </span>2007 Feb;<span class="ref-vol">7</span>(2):440–7.</span> [<a href="/pubmed/17173657" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17173657</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.brunettipierri.2012.248">Brunetti-Pierri N, Lamance KM, Lewis RA, Craigen WJ. 30-year follow-up of a patient with classic citrullinemia. <span><span class="ref-journal">Mol Genet Metab. </span>2012;<span class="ref-vol">106</span>:248–50.</span> [<a href="/pubmed/22494546" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22494546</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.brusilow.2001">Brusilow SW, Horwich AL. Urea cycle enzymes. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, eds. <em>The Metabolic &#x00026; Molecular Bases of Inherited Diseases.</em> Chap 85. 8 ed. 2001.</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.chadefauxvekemans.2002.456">Chadefaux-Vekemans B, Rabier D, Chabli A, Blanc A, Aupetit J, Bardet J, Kamoun P. Improving the prenatal diagnosis of citrullinemia using citrulline/ornithine+arginine ratio in amniotic fluid. <span><span class="ref-journal">Prenat Diagn. </span>2002;<span class="ref-vol">22</span>:456–8.</span> [<a href="/pubmed/12116302" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12116302</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.engel.2009.300">Engel K, H&#x000f6;hne W, H&#x000e4;berle J. Mutations and polymorphisms in the human argininosuccinate synthetase (ASS1) gene. <span><span class="ref-journal">Hum Mutat. </span>2009;<span class="ref-vol">30</span>:300–7.</span> [<a href="/pubmed/19006241" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19006241</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.faghfoury.2011.413">Faghfoury H, Baruteau J, de Baulny HO, H&#x000e4;berle J, Schulze A. Transient fulminant liver failure as an initial presentation in citrullinemia type I. <span><span class="ref-journal">Mol Genet Metab. </span>2011;<span class="ref-vol">102</span>:413–7.</span> [<a href="/pubmed/21227727" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21227727</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.gao.2003.24">Gao HZ, Kobayashi K, Tabata A, Tsuge H, Iijima M, Yasuda T, Kalkanoglu HS, Dursun A, Tokatli A, Coskun T, Trefz FK, Skladal D, Mandel H, Seidel J, Kodama S, Shirane S, Ichida T, Makino S, Yoshino M, Kang JH, Mizuguchi M, Barshop BA, Fuchinoue S, Seneca S, Zeesman S, Knerr I, Rod&#x000e9;s M, Wasant P, Yoshida I, De Meirleir L, Abdul Jalil M, Begum L, Horiuchi M, Katunuma N, Nakagawa S, Saheki T. Identification of 16 novel mutations in the argininosuccinate synthetase gene and genotype-phenotype correlation in 38 classical citrullinemia patients. <span><span class="ref-journal">Hum Mutat. </span>2003;<span class="ref-vol">22</span>:24–34.</span> [<a href="/pubmed/12815590" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12815590</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.g__er.2004.541">G&#x000fc;&#x000e7;er S, A&#x0015f;an E, Atilla P, Tokatli A, Ca&#x0011f;lar M. Early cirrhosis in a patient with type I citrullinaemia (CTLN1). <span><span class="ref-journal">J Inherit Metab Dis. </span>2004;<span class="ref-vol">27</span>:541–2.</span> [<a href="/pubmed/15334737" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15334737</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.h_berle.2012.32">H&#x000e4;berle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M, Karall D, Martinelli D, Crespo PS, Santer R, Servais A, Valayannopoulos V, Lindner M, Rubio V, Dionisi-Vici C. Suggested guidelines for the diagnosis and management of urea cycle disorders. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2012;<span class="ref-vol">7</span>:32.</span> [<a href="/pmc/articles/PMC3488504/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3488504</span></a>] [<a href="/pubmed/22642880" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22642880</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.h_berle.2009.1">H&#x000e4;berle J, Meli C, Parini R, Rigoldi M, Vilaseca M. Severe first manifestation of citrullinemia type I in the postpartum period. <span><span class="ref-journal">Mol Genet Metab. </span>2009;<span class="ref-vol">98</span>:1–2.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.h_berle.2002.327">H&#x000e4;berle J, Pauli S, Linnebank M, Kleijer WJ, Bakker HD, Wanders RJ, Harms E, Koch HG. Structure of the human argininosuccinate synthetase gene and an improved system for molecular diagnostics in patients with classical and mild citrullinemia. <span><span class="ref-journal">Hum Genet. </span>2002;<span class="ref-vol">110</span>:327–33.</span> [<a href="/pubmed/11941481" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11941481</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.h_berle.2003.302">H&#x000e4;berle J, Pauli S, Schmidt E, Schulze-Eilfing B, Berning C, Koch HG. Mild citrullinemia in Caucasians is an allelic variant of argininosuccinate synthetase deficiency (citrullinemia type 1). <span><span class="ref-journal">Mol Genet Metab. </span>2003;<span class="ref-vol">80</span>:302–6.</span> [<a href="/pubmed/14680976" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14680976</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.h_berle.2010.228">H&#x000e4;berle J, Vilaseca MA, Meli C, Rigoldi M, Jara F, Vecchio I, Capra C, Parini R. First manifestation of citrullinemia type I as differential diagnosis to postpartum psychosis in the puerperal period. <span><span class="ref-journal">Eur J Obstet Gynecol Reprod Biol. </span>2010;<span class="ref-vol">149</span>:228–9.</span> [<a href="/pubmed/20005624" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20005624</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.haviv.2014.243">Haviv R, Zeharia A, Belaiche C, Haimi Cohen Y, Saada A. Elevated plasma citrulline: look for dihydrolipoamide dehydrogenase deficiency. <span><span class="ref-journal">Eur J Pediatr. </span>2014;<span class="ref-vol">173</span>:243–5.</span> [<a href="/pubmed/23995961" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23995961</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.ito.2003.87">Ito T, Sumi S, Kidouchi K, Ban K, Ueta A, Hashimoto T, Togari H, Wada Y. Allopurinol challenge tests performed before and after living-related donor liver transplantation in citrullinaemia. <span><span class="ref-journal">J Inherit Metab Dis. </span>2003;<span class="ref-vol">26</span>:87–8.</span> [<a href="/pubmed/12872848" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12872848</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.kasper.2010.607">Kasper DC, Ratschmann R, Metz TF, Mechtler TP, M&#x000f6;slinger D, Konstantopoulou V, Item CB, Pollak A, Herkner KR. The national Austrian newborn screening program - eight years&#x02019; experience with mass spectrometry. past, present, and future goals. <span><span class="ref-journal">Wien Klin Wochenschr. </span>2010;<span class="ref-vol">122</span>:607–13.</span> [<a href="/pubmed/20938748" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20938748</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.kim.2013.158">Kim IK, Niemi AK, Krueger C, Bonham CA, Concepcion W, Cowan TM, Enns GM, Esquivel CO. Liver transplantation for urea cycle disorders in pediatric patients: a single-center experience. <span><span class="ref-journal">Pediatr Transplant. </span>2013;<span class="ref-vol">17</span>:158–67.</span> [<a href="/pubmed/23347504" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23347504</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.lar_vere.2009.1166">Lar&#x000f3;vere LE, Angaroni CJ, Antonozzi SL, Bezard MB, Shimohama M, de Kremer RD. Citrullinemia type I, classical variant. Identification of ASS-p~G390R (c.1168G&#x0003e;A) mutation in families of a limited geographic area of Argentina: a possible population cluster. <span><span class="ref-journal">Clin Biochem. </span>2009;<span class="ref-vol">42</span>:1166–8.</span> [<a href="/pubmed/19358837" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19358837</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.lee.2013.18">Lee BH, Kim YM, Heo SH, Kim GH, Choi IH, Lee BS, Kim EA, Kim KS, Jhang WK, Park SJ, Yoo HW. High prevalence of neonatal presentation in Korean patients with citrullinemia type 1, and their shared mutations. <span><span class="ref-journal">Mol Genet Metab. </span>2013;<span class="ref-vol">108</span>:18–24.</span> [<a href="/pubmed/23246278" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23246278</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.majoie.2004.32">Majoie CBLM, Mourmans JM, Akkerman EM, Duran M, Poll-The BT. Neonatal citrullinemia: comparison of conventional MR, diffusion-weighted, and diffusion tensor findings. <span><span class="ref-journal">AJNR Am J Neuroradiol. </span>2004;<span class="ref-vol">25</span>:32–5.</span> [<a href="/pubmed/14729525" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14729525</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.marsden.2003.111">Marsden D. Expanded newborn screening by tandem mass spectrometry: the Massachusetts and New England experience. <span><span class="ref-journal">Southeast Asian J Trop Med Public Health. </span>2003;<span class="ref-vol">34</span>:111–4.</span> [<a href="/pubmed/15906712" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15906712</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.morioka.2005.1332">Morioka D, Kasahara M, Takada Y, Shirouzu Y, Taira K, Sakamoto S, Uryuhara K, Egawa H, Shimada H, Tanaka K. Current role of liver transplantation for the treatment of urea cycle disorders: a review of the worldwide English literature and 13 cases at Kyoto University. <span><span class="ref-journal">Liver Transpl. </span>2005;<span class="ref-vol">11</span>:1332–42.</span> [<a href="/pubmed/16237708" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16237708</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.niu.2010.s295">Niu DM, Chien YH, Chiang CC, Ho HC, Hwu WL, Kao SM, Chiang SH, Kao CH, Liu TT, Chiang H, Hsiao KJ. Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan. <span><span class="ref-journal">J Inherit Metab Dis. </span>2010;<span class="ref-vol">33</span>:S295–305.</span> [<a href="/pubmed/20567911" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20567911</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.perito.2014.89">Perito ER, Rhee S, Roberts JP, Rosenthal P. Pediatric liver transplantation for urea cycle disorders and organic acidemias: United Network for Organ Sharing data for 2002-2012. <span><span class="ref-journal">Liver Transpl. </span>2014;<span class="ref-vol">20</span>:89–99.</span> [<a href="/pmc/articles/PMC3877181/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3877181</span></a>] [<a href="/pubmed/24136671" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24136671</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.potter.2004.77">Potter MA, Zeesman S, Brennan B, Kobayashi K, Gao HZ, Tabata A, Saheki T, Whelan DT. Pregnancy in a healthy woman with untreated citrullinemia. <span><span class="ref-journal">Am J Med Genet A. </span>2004;<span class="ref-vol">129A</span>:77–82.</span> [<a href="/pubmed/15266621" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15266621</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.r_egger.2014.21">R&#x000fc;egger CM, Lindner M, Ballhausen D, Baumgartner MR, Beblo S, Das A, Gautschi M, Glahn EM, Gr&#x000fc;nert SC, Hennermann J, Hochuli M, Huemer M, Karall D, K&#x000f6;lker S, Lachmann RH, Lotz-Havla A, M&#x000f6;slinger D, Nuoffer JM, Plecko B, Rutsch F, Santer R, Spiekerkoetter U, Staufner C, Stricker T, Wijburg FA, Williams M, Burgard P, H&#x000e4;berle J. Cross-sectional observational study of 208 patients with non-classical urea cycle disorders. <span><span class="ref-journal">J Inherit Metab Dis. </span>2014;<span class="ref-vol">37</span>:21–30.</span> [<a href="/pmc/articles/PMC3889631/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3889631</span></a>] [<a href="/pubmed/23780642" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23780642</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.ruitenbeek.2003.102">Ruitenbeek W, Kobayashi K, Iijima M, Smeitink JA, Engelke UF, De Abreu RA, Kwast HT, Saheki T, Boelen CA, De Jong JG, Wevers RA. Moderate citrullinaemia without hyperammonaemia in a child with mutated and deficient argininosuccinate synthetase. <span><span class="ref-journal">Ann Clin Biochem. </span>2003;<span class="ref-vol">40</span>:102–7.</span> [<a href="/pubmed/12542919" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12542919</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.saheki.2002.333">Saheki T, Kobayashi K. Mitochondrial aspartate glutamate carrier (citrin) deficiency as the cause of adult-onset type II citrullinemia (CTLN2) and idiopathic neonatal hepatitis (NICCD). <span><span class="ref-journal">J Hum Genet. </span>2002;<span class="ref-vol">47</span>:333–41.</span> [<a href="/pubmed/12111366" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12111366</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.salek.2010.1049">Salek J, Byrne J, Box T, Longo N, Sussman N. Recurrent liver failure in a 25-year-old female. <span><span class="ref-journal">Liver Transpl. </span>2010;<span class="ref-vol">16</span>:1049–53.</span> [<a href="/pubmed/20818742" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20818742</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.summar.2001.s30">Summar M. Current strategies for the management of neonatal urea cycle disorders. <span><span class="ref-journal">J Pediatr. </span>2001;<span class="ref-vol">138</span>:S30–9.</span> [<a href="/pubmed/11148547" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11148547</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.summar.2013.179">Summar ML, Koelker S, Freedenberg D, Le Mons C, Haberle J, Lee HS, Kirmse B., European Registry and Network for Intoxication Type Metabolic Diseases (E-IMD).  Members of the Urea Cycle Disorders Consortium (UCDC). The incidence of urea cycle disorders. <span><span class="ref-journal">Mol Genet Metab. </span>2013;<span class="ref-vol">110</span>:179–80.</span> [<a href="/pmc/articles/PMC4364413/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4364413</span></a>] [<a href="/pubmed/23972786" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23972786</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF39">UCD Conference Group. Consensus statement from a conference for the management of patients with urea cycle disorders. <span><span class="ref-journal">J Pediatr. </span>2001;<span class="ref-vol">138</span>:S1–5.</span> [<a href="/pubmed/11148543" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11148543</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctlm.REF.yoon.2003.115">Yoon HR, Lee KR, Kim H, Kang S, Ha Y, Lee DH. Tandem mass spectrometric analysis for disorders in amino, organic and fatty acid metabolism: two year experience in South Korea. <span><span class="ref-journal">Southeast Asian J Trop Med Public Health. </span>2003;<span class="ref-vol">34</span>:115–20.</span> [<a href="/pubmed/15906713" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15906713</span></a>]</div></li></ul></div></div><div id="ctlm.Chapter_Notes"><h2 id="_ctlm_Chapter_Notes_">Chapter Notes</h2><div id="ctlm.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>1 September 2016 (ma) Comprehensive update posted live</div></li><li class="half_rhythm"><div>23 January 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>11 August 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>2 June 2009 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>22 April 2008 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> available clinically</div></li><li class="half_rhythm"><div>22 December 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 July 2004 (me) Review posted live</div></li><li class="half_rhythm"><div>9 February 2004 (jt) Original submission</div></li></ul></div></div><div style="display:none"><div id="figucdoverviewF1"><img alt="Image ucd-overview-Image001" src-large="/books/n/gene/ucd-overview/bin/ucd-overview-Image001.jpg" /></div><div id="figucdoverviewF3"><img alt="Image ucd-overview-Image003" src-large="/books/n/gene/ucd-overview/bin/ucd-overview-Image003.jpg" /></div><div id="figucdoverviewF2"><img alt="Image ucd-overview-Image002" src-large="/books/n/gene/ucd-overview/bin/ucd-overview-Image002.jpg" /></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1458</span><span class="label">PMID: <a href="/pubmed/20301631" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301631</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/citrin/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/eds/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1458&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1458/?report=reader">PubReader</a></li><li><a href="/books/NBK1458/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1458" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1458" style="display:none" title="Cite this Page"><div class="bk_tt">Quinonez SC, Thoene JG. Citrullinemia Type I. 2004 Jul 7 [Updated 2016 Sep 1]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1458/pdf/Bookshelf_NBK1458.pdf">PDF version of this page</a> (459K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#ctlm.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#ctlm.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#ctlm.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#ctlm.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#ctlm.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#ctlm.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#ctlm.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#ctlm.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#ctlm.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#ctlm.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#ctlm.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=445[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ASS1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1473480" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1473480" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1473480" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1473480" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21290785" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Argininosuccinate Lyase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Argininosuccinate Lyase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nagamani SCS, Erez A, Lee B. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22649802" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Camacho J, Rioseco-Camacho N. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24006547" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22593918" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Propionic Acidemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Propionic Acidemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Shchelochkov OA, Carrillo N, Venditti C. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301360" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Citrin Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Citrin Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Saheki T, Song YZ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301631" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301631" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e042977dde08911699f3553">Citrullinemia Type I - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Citrullinemia Type I - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T22:31:03-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE89C0A0E0415671000000000A8304D0&amp;ncbi_session=CE89C0A0E0429771_2691SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1458%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1458&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1458/&amp;ncbi_pagename=Citrullinemia Type I - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE89C0A0E0429771_2691SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>